A liquid crystal compound is provided that satisfies at least one physical property, such as high stability to heat and light, a high clearing point (or high maximum temperature), a low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy, large negative dielectric anisotropy, a suitable elastic constant and good compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound, and a liquid crystal display device including the composition. The liquid crystal compound is represented by formula (1): ##STR00001##
in which, R.sup.a and R.sup.b are alkyl having 1 to 10 carbons; ring A.sup.1, ring A.sup.2 and ring A.sup.3 are 1,4-cyclohexylene, 1,4-phenylene; and ring N.sup.1 is 2,3-difluoro-1,4-phenylene; G is a divalent group represented by formula (pr-1) or (pr-2); ##STR00002##
in which, Z.sup.1, Z.sup.2, Z.sup.3 and Z.sup.4 are a single bond; and a, b and c are 0, 1 or 2.

A liquid crystal compound is provided that satisfies at least one physical property, such as high stability to heat and light, a high clearing point (or high maximum temperature), a low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy, large negative dielectric anisotropy, a suitable elastic constant and good compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound, and a liquid crystal display device including the composition. The liquid crystal compound is represented by formula (1): ##STR00001##
in which, R.sup.a and R.sup.b are alkyl having 1 to 10 carbons; ring A.sup.1, ring A.sup.2 and ring A.sup.3 are 1,4-cyclohexylene, 1,4-phenylene; and ring N.sup.1 is 2,3-difluoro-1,4-phenylene; G is a divalent group represented by formula (pr-1) or (pr-2); ##STR00002##
in which, Z.sup.1, Z.sup.2, Z.sup.3 and Z.sup.4 are a single bond; and a, b and c are 0, 1 or 2.

The present application discloses a compound which is

##STR00001##

which activates Wnt/β-catenin signaling and thus treats or prevents diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

The present invention provides turn-ON dioxetane-based chemiluminescence probes based on the Schapp's adamantylidene-dioxetane probe, which emit light in the near-infrared (NIR) region and are therefore useful for in vivo imaging, as well as compositions and uses thereof.

The present invention provides turn-ON dioxetane-based chemiluminescence probes based on the Schapp's adamantylidene-dioxetane probe, which emit light in the near-infrared (NIR) region and are therefore useful for in vivo imaging, as well as compositions and uses thereof.

A compound inhibiting Hsp90 and a pharmaceutical composition including the same as an active ingredient are described, which compound is represented by formula 2 and suppresses the expression of Hsp90, inhibits the accumulation of HIF-1α, the Hsp90 client protein, and efficiently inhibits the activation of VEGF. The compound displays low cytotoxicity and can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.

A compound inhibiting Hsp90 and a pharmaceutical composition including the same as an active ingredient are described, which compound is represented by formula 2 and suppresses the expression of Hsp90, inhibits the accumulation of HIF-1α, the Hsp90 client protein, and efficiently inhibits the activation of VEGF. The compound displays low cytotoxicity and can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.

The invention provides a method for the preparation of regioisomerically pure intermediates which are useful for the preparation of carboxy-fluorescein-type compounds. Such compounds have broad applications within bio-conjugation and/or fluorescent imaging.

The present disclosure provides a compound of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

The present disclosure provides a compound of Formula (I):

##STR00001##

or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.